MCID: TNG003
MIFTS: 59

Tongue Cancer

Categories: Rare diseases, Cancer diseases, Oral diseases, Gastrointestinal diseases

Aliases & Classifications for Tongue Cancer

MalaCards integrated aliases for Tongue Cancer:

Name: Tongue Cancer 12 53 55 15
Tongue Carcinoma 53 55 73
Malignant Neoplasm of Tongue 12 73
Tongue Neoplasms 44 73
Malignant Neoplasm of Tip and/or Lateral Border of Tongue 12
Malignant Neoplasm of Tip and Lateral Border of Tongue 12
Malignant Neoplasm of Tongue, Tip and Lateral Border 12
Malignant Neoplasm of Anterior Two-Thirds of Tongue 12
Malignant Tumor of Anterior Two-Thirds of Tongue 12
Malignant Neoplasm of Junctional Zone of Tongue 12
Malignant Neoplasm of Ventral Surface of Tongue 12
Malignant Neoplasm of Dorsal Surface of Tongue 12
Malignant Neoplasm of Anterior 2/3 of Tongue 12
Malignant Neoplasm of Ventral Tongue Surface 12
Malignant Neoplasm of Mobile Part of Tongue 12
Malignant Neoplasm of Other Sites of Tongue 12
Malignant Neoplasm of Fixed Part of Tongue 12
Malignant Tumor of Mobile Part of Tongue 12
Malignant Neoplasm of Border of Tongue 12
Malignant Neoplasm of Dorsum of Tongue 12
Malignant Neoplasm of Base of Tongue 12
Malignant Neoplasm of Lingual Tonsil 12
Malignant Neoplasm of Dorsal Tongue 12
Malignant Tumor of Posterior Tongue 12
Malignant Tumor of Base of Tongue 12
Malignant Tumor of Lingual Tonsil 12
Malignant Tumor of Tongue 12
Tongue Neoplasm Malignant 12
Tongue Neoplasm 76

Classifications:



Summaries for Tongue Cancer

MalaCards based summary : Tongue Cancer, also known as tongue carcinoma, is related to oropharynx cancer and periodontitis, and has symptoms including glossalgia An important gene associated with Tongue Cancer is MALAT1 (Metastasis Associated Lung Adenocarcinoma Transcript 1
In the present study, lncRNA-MALAT1 was specifically upregulated in tongue cancer cell lines and overexpression promoted tongue cancer cell growth by targeting miR-124.
Dysfunction Pattern: Regulation [up-regulated]), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Endometrial cancer. The drugs Nicotine and Liver Extracts have been mentioned in the context of this disorder. Affiliated tissues include tongue, tonsil and lung, and related phenotypes are homeostasis/metabolism and immune system

Wikipedia : 76 Oral cancer, also known as mouth cancer, is a type of head and neck cancer and is any cancerous tissue... more...

Related Diseases for Tongue Cancer

Diseases related to Tongue Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 158)
# Related Disease Score Top Affiliating Genes
1 oropharynx cancer 29.8 CDKN2A MMP8 TP53
2 periodontitis 29.7 MMP2 MMP8 MMP9
3 squamous cell carcinoma 29.1 BCYRN1 CDH1 CDKN2A MALAT1 TP53
4 papilloma 29.0 CDKN1A CDKN2A KRT13 TP53
5 oral cancer 28.1 CDH1 CDKN2A KRT13 MMP2 MMP9 TP53
6 tongue squamous cell carcinoma 27.8 CDH1 CDKN2A MALAT1 MMP2 MMP9 TP53
7 nasopharyngeal carcinoma 26.0 CDH1 CDKN2A KRT13 MALAT1 MMP9 TERT
8 esophageal cancer 25.1 BCYRN1 CDH1 CDKN1A CDKN2A MALAT1 MMP2
9 lung cancer 25.0 BCYRN1 CDH1 CDKN1A CDKN2A MALAT1 MMP2
10 cerebral convexity meningioma 10.9 CDH1 TP53
11 actinic cheilitis 10.9 CDKN1A TP53
12 invasive bladder transitional cell carcinoma 10.8 CDKN1A TP53
13 bladder transitional cell papilloma 10.8 CDKN1A TP53
14 atypical follicular adenoma 10.8 CDKN1A TP53
15 extracranial arteriovenous malformation 10.7 MMP2 MMP9
16 brain stem astrocytic neoplasm 10.7 CDKN2A TP53
17 focal myositis 10.7 MMP2 MMP9
18 spastic entropion 10.7 MMP2 MMP9
19 lentigo maligna melanoma 10.6 MMP2 MMP9
20 vulvar intraepithelial neoplasia 10.6 CDH1 MMP2 TP53
21 villous adenocarcinoma 10.6 MMP2 MMP9
22 psammomatous meningioma 10.6 MMP2 MMP9
23 anaplastic thyroid cancer 10.6 CDH1 CDKN1A TP53
24 ovarian cancer 1 10.6 CDH1 MMP2 TP53
25 malignant ovarian surface epithelial-stromal neoplasm 10.6 CDH1 MMP2 TP53
26 ovary epithelial cancer 10.6 CDH1 MMP2 TP53
27 keratinizing squamous cell carcinoma 10.6 CDKN2A TP53
28 acute transverse myelitis 10.6 MMP2 MMP9
29 brain glioblastoma multiforme 10.6 MMP9 TP53
30 amaurosis fugax 10.6 MMP8 MMP9
31 senile ectropion 10.6 MMP2 MMP9
32 spitz nevus 10.6 CDKN2A TP53
33 bladder carcinoma in situ 10.6 CDKN2A TP53
34 internal hemorrhoid 10.6 MMP2 MMP9
35 bartholin's gland benign neoplasm 10.5 CDKN2A TP53
36 ischemic colitis 10.5 MMP2 MMP9
37 breast carcinoma in situ 10.5 CDH1 TP53 VEGFC
38 thyroid lymphoma 10.5 CDKN2A TP53
39 parotitis 10.5 MMP2 MMP9
40 gallbladder cancer 10.5 CDH1 MALAT1 TP53
41 infiltrating angiolipoma 10.5 CDKN2A VEGFC
42 nasal cavity adenocarcinoma 10.5 CDKN2A TP53
43 breast ductal carcinoma 10.5 CDH1 TP53 VEGFC
44 bladder urothelial carcinoma 10.4 CDH1 MALAT1 TP53
45 male reproductive organ cancer 10.4 CDH1 MMP9 TP53
46 microcystic meningioma 10.4 CDH1 MMP2 MMP9
47 bone squamous cell carcinoma 10.4 CDKN2A TP53
48 lung giant cell carcinoma 10.4 CDH1 MMP2 MMP9
49 pre-malignant neoplasm 10.4 CDH1 CDKN2A TP53
50 scrotal carcinoma 10.4 CDKN2A TP53

Comorbidity relations with Tongue Cancer via Phenotypic Disease Network (PDN):


Protein-Energy Malnutrition Swallowing Disorders

Graphical network of the top 20 diseases related to Tongue Cancer:



Diseases related to Tongue Cancer

Symptoms & Phenotypes for Tongue Cancer

UMLS symptoms related to Tongue Cancer:


glossalgia

MGI Mouse Phenotypes related to Tongue Cancer:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.96 MMP8 MMP9 PRLR TERT TP53 CDH1
2 immune system MP:0005387 9.81 MMP8 MMP9 TERT TP53 CDH1 VEGFC
3 neoplasm MP:0002006 9.61 MMP9 PRLR TERT TP53 CDH1 CDKN1A
4 respiratory system MP:0005388 9.1 MMP9 TERT TP53 CDKN1A CDKN2A MMP2

Drugs & Therapeutics for Tongue Cancer

Drugs for Tongue Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 149)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicotine Approved Phase 4,Not Applicable 54-11-5 942 89594
2 Liver Extracts Phase 4,Phase 2,Phase 1,Not Applicable
3 Central Nervous System Stimulants Phase 4,Not Applicable
4 Cholinergic Agents Phase 4,Phase 2,Phase 3,Not Applicable
5 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
6 Nicotinic Agonists Phase 4,Not Applicable
7 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Not Applicable
8 Autonomic Agents Phase 4,Phase 2,Phase 3,Not Applicable
9
Cisplatin Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 15663-27-1 84093 441203 2767
10
Cetuximab Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 205923-56-4 56842117 2333
11
Docetaxel Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 114977-28-5 148124
12
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
13
Aldesleukin Approved Phase 3 85898-30-2, 110942-02-4
14
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
15
Pilocarpine Approved, Investigational Phase 2, Phase 3 54-71-7, 92-13-7 5910
16
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
17
Doxepin Approved, Investigational Phase 3 1668-19-5 667477 667468
18
Bevacizumab Approved, Investigational Phase 3,Phase 2 216974-75-3
19 Interleukin-2 Phase 3
20 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
21 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
22 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
23 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
24 Anti-HIV Agents Phase 3,Phase 2
25 Anti-Retroviral Agents Phase 3,Phase 2
26 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable
27 Antiviral Agents Phase 3,Phase 2,Not Applicable
28 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
29 Antimitotic Agents Phase 2, Phase 3,Phase 3,Phase 1
30
Histamine Phosphate Phase 3 51-74-1 65513
31 Mitogens Phase 3,Phase 2,Phase 1
32 Histamine Antagonists Phase 3
33 Vaccines Phase 3,Phase 1
34 Antibodies Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
35 Immunoglobulins Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
36 Antibodies, Monoclonal Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
37 Antidepressive Agents Phase 3
38 Antidepressive Agents, Tricyclic Phase 3
39 Psychotropic Drugs Phase 3
40 Endothelial Growth Factors Phase 3
41 Immunoglobulin G Phase 3
42
Tegafur Approved, Investigational Phase 2 17902-23-7 5386
43
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
44
Indinavir Approved Phase 2 150378-17-9 5362440
45
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
46
Zinc Approved, Investigational Phase 2 7440-66-6 23994
47
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
48
Sorafenib Approved, Investigational Phase 2,Phase 1 284461-73-0 216239 406563
49
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
50
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838

Interventional clinical trials:

(show top 50) (show all 102)
# Name Status NCT ID Phase Drugs
1 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
2 PET/CT Scan-Guided Watchful Waiting or Neck Dissection of Locally Advanced Lymph Node Metastases in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Primary Head And Neck Cancer Unknown status NCT00720070 Phase 3
3 Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or Oropharynx Unknown status NCT00002702 Phase 3
4 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
5 Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive Tract Completed NCT00765440 Phase 3
6 Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
7 Phase II Trial of Allovectin-7® for Head and Neck Cancer Completed NCT00050388 Phase 3
8 Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Active, not recruiting NCT01810913 Phase 2, Phase 3 cisplatin;docetaxel
9 Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer Active, not recruiting NCT00956007 Phase 3
10 Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Active, not recruiting NCT00588770 Phase 3 Carboplatin;Cisplatin;Docetaxel;Fluorouracil
11 Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients Who Have Undergone Surgery for Advanced Hypopharyngeal Cancer, Oropharyngeal Cancer, Laryngeal Cancer, or Oral Cavity Cancer at High Risk of Recurrence Withdrawn NCT01142414 Phase 3 cisplatin;fluorouracil
12 CETUXIMAB Given for 3 Weeks as Neoadjuvant Treatment in Locally Advanced Tongue Cancer ; A NEW PARADIGM OF TREATMENT Unknown status NCT01760811 Phase 1, Phase 2 Erbitux,merck serono
13 Neoadjuvant Chemotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN) Unknown status NCT01312350 Phase 2 neoadjuvant docetaxel/cisplatin/fluorouracil;No treatment before definitive CCRT
14 Trial of E10A in Head and Neck Cancer Unknown status NCT00634595 Phase 2 E10A;Cisplatin;Paclitaxel
15 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
16 Docetaxel and S-1 Followed By Radiation Therapy and Low-Dose Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer Unknown status NCT00625937 Phase 2 cisplatin;docetaxel;tegafur-gimeracil-oteracil potassium
17 Cetuximab and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Oropharynx Cancer That Can Be Removed by Surgery Completed NCT00665392 Phase 2 cisplatin;docetaxel;fluorouracil;Cetuximab
18 Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia Completed NCT00330382 Phase 2 Bowman-Birk inhibitor concentrate
19 Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer Completed NCT01084083 Phase 2 Paclitaxel;Cisplatin
20 Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx Completed NCT00064103 Phase 1, Phase 2
21 Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. Completed NCT01469429 Phase 1, Phase 2 chemoprevention;chemoprevention
22 Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer Completed NCT01316757 Phase 2 paclitaxel;carboplatin;erlotinib hydrochloride
23 Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab Completed NCT00939627 Phase 2 sorafenib tosylate
24 Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00513435 Phase 2 saracatinib
25 Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00507767 Phase 2 dasatinib
26 Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Completed NCT00114283 Phase 2 lapatinib ditosylate
27 Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Completed NCT00103259 Phase 2 bortezomib;irinotecan hydrochloride
28 S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00096512 Phase 2 sorafenib tosylate
29 Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck Completed NCT00033618 Phase 2 ixabepilone
30 Celecoxib in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia Completed NCT00101335 Phase 2 celecoxib
31 Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery Completed NCT02007200 Phase 2 Soy Isoflavones
32 Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy Completed NCT01256385 Phase 2 Temsirolimus
33 Everolimus, Carboplatin, and Paclitaxel in Locally Advanced Head and Neck Cancer That Cannot Be Removed by Surgery Completed NCT01333085 Phase 1, Phase 2 carboplatin;RAD001;paclitaxel
34 Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma Completed NCT01195922 Phase 1, Phase 2 Sirolimus
35 Chemotherapy, Radiation Therapy, and Cetuximab in Treating Patients With the Head and Neck Cancer Completed NCT00875849 Phase 2 cisplatin
36 Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Cisplatin, and Cetuximab Given Together With Radiation Therapy in Treating Patients With Locally Advanced Stage III or Stage IV Head and Neck Cancer Completed NCT00851877 Phase 1, Phase 2 cisplatin;paclitaxel albumin-stabilized nanoparticle formulation
37 Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Completed NCT00833261 Phase 2 cetuximab;cisplatin
38 Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer Completed NCT00458978 Phase 2 Cediranib Maleate
39 Cisplatin, Bevacizumab, and Intensity-Modulated Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer Completed NCT00423930 Phase 2 cisplatin
40 Zinc Supplements in Lowering Cadmium Levels in Smokers Completed NCT00376987 Phase 2
41 Correlation of FAZA PET Hypoxia Imaging To 3D Histology in Oral Tongue Cancer Recruiting NCT03181035 Phase 1, Phase 2 Pimonidazole
42 High-activity Natural Killer Immunotherapy for Small Metastases of Tongue Cancer Recruiting NCT03008330 Phase 1, Phase 2
43 Combination of Cryosurgey and NK Immunotherapy for Recurrent Tongue Cancer Recruiting NCT02849379 Phase 1, Phase 2
44 A Dye for the Detection of Cancer of the Tongue and Mouth Recruiting NCT03085147 Phase 1, Phase 2 Olaparib
45 Effect of COX-2 and EGFR Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study Recruiting NCT02748707 Phase 2 Arm1;Arm 2;Arm 3
46 Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer Active, not recruiting NCT02254278 Phase 2 Cisplatin
47 PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Active, not recruiting NCT01816984 Phase 1, Phase 2 PI3K inhibitor BKM120
48 18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy Active, not recruiting NCT01806675 Phase 1, Phase 2 fludeoxyglucose F 18;2-fluoropropionyl-labeled pegylated dimeric RGD peptide
49 Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma Active, not recruiting NCT01175980 Phase 2 Vorinostat
50 A Study of Tongue Conservation Surgery for Oral Tongue Cancer Terminated NCT03161548 Phase 2 Induction chemotherapy

Search NIH Clinical Center for Tongue Cancer

Cochrane evidence based reviews: tongue neoplasms

Genetic Tests for Tongue Cancer

Anatomical Context for Tongue Cancer

MalaCards organs/tissues related to Tongue Cancer:

41
Tongue, Tonsil, Lung, Lymph Node, Liver, Endothelial, Brain

Publications for Tongue Cancer

Articles related to Tongue Cancer:

(show top 50) (show all 516)
# Title Authors Year
1
Risk of oral tongue cancer among immunocompromised transplant recipients and human immunodeficiency virus-infected individuals in the United States. ( 29645080 )
2018
2
Depth of invasion on pathological outcomes in clinical low-stage oral tongue cancer patients. ( 29750853 )
2018
3
Long-term outcome of high-dose-rate brachytherapy and perioperative brachytherapy in early mobile tongue cancer. ( 29619058 )
2018
4
Long noncoding RNA Lnca89EGFR promotes cell proliferation and inhibits cell apoptosis via regulating the expression of EGFR in human tongue cancer. ( 29138845 )
2018
5
Distribution of cervical metastasis in tongue cancer: Are occult metastases predictable? A retrospective study of 117 oral tongue carcinomas. ( 29174473 )
2018
6
Patterns of recurrence in oral tongue cancer with perineural invasion. ( 29522275 )
2018
7
Survival and recurrence of resectable tongue cancer: Resection margin cutoff value by T classification. ( 28960654 )
2018
8
Effects of low-intensity ultrasound combined with low-dose carboplatin in an orthotopic hamster model of tongue cancer: A preclinical study. ( 29436690 )
2018
9
Angiogenesis and evading immune destruction are the main related transcriptomic characteristics to the invasive process of oral tongue cancer. ( 29386520 )
2018
10
Effect of induction chemotherapy on the quality-of-life in patients with advanced stage tongue cancer by a prospective study. ( 29332408 )
2018
11
Simple laryngeal suspension procedure by suturing the digastric muscle to the periosteum of the mandible in neck dissection for tongue cancer. ( 29395281 )
2018
12
Differences between epithelial and mesenchymal human tongue cancer cell lines in experimental metastasis. ( 29928368 )
2018
13
Efficacy of postoperative neck irradiation for regional control in patients with pN0 oral tongue cancer: Propensity analysis. ( 29083541 )
2018
14
Tongue cancer epidemiology in Brazil: incidence, morbidity and mortality. ( 29626365 )
2018
15
Survival benefits of adjuvant radiation in the management of early tongue cancer with depth of invasion as the indication. ( 29947144 )
2018
16
Base of tongue cancer-is it tongue cancer located at the base of the tongue, or is it a type of lingual tonsil cancer? The perspective from a genomic analysis. ( 29452725 )
2018
17
LncRNA KCNQ1OT1 regulates proliferation and cisplatin resistance in tongue cancer via miR-211-5p mediated Ezrin/Fak/Src signaling. ( 29970910 )
2018
18
Functional evaluation of swallowing in patients with tongue cancer before and after surgery using high-speed continuous magnetic resonance imaging based on T2-weighted sequences. ( 29128287 )
2018
19
LpMab-23-recognizing cancer-type podoplanin is a novel predictor for a poor prognosis of early stage tongue cancer. ( 29765527 )
2018
20
Endothelin Signaling Contributes to Modulation of Nociception in Early-stage Tongue Cancer in Rats. ( 29461271 )
2018
21
Cancer-associated i-8broblasts confer cisplatin resistance of tongue cancer via autophagy activation. ( 29156523 )
2018
22
Chemoradiotherapy using retrograde superselective intra-arterial infusion for tongue cancer: Analysis of therapeutic results in 118 cases. ( 29598953 )
2018
23
Stage II Oral Tongue Cancer: Survival Impact of Adjuvant Radiation Based on Depth of Invasion. ( 29944460 )
2018
24
Classification of tongue cancer resection and treatment algorithm. ( 29432642 )
2018
25
Protein Expression in Tonsillar and Base of Tongue Cancer and in Relation to Human Papillomavirus (HPV) and Clinical Outcome. ( 29587383 )
2018
26
Evaluation of the budding and depth of invasion (BD) model in oral tongue cancer biopsies. ( 28766010 )
2017
27
Evidence of phenotypic stability after transduction of fluorescent proteins in two human tongue cancer cell lines. ( 28288391 )
2017
28
Effectiveness of radiotherapy+ozone on tumoral tissue and survival in tongue cancer rat model. ( 28390748 )
2017
29
A Retrospective Evaluation of Partial Glossectomy for Early Tongue Cancer Using a Carbon Dioxide Laser. ( 28358663 )
2017
30
Intraoperative Ultrasound in Oral Tongue Cancer Resection: Feasibility Study and Early Outcomes. ( 29161194 )
2017
31
Histamine H4 receptor signalling in tongue cancer and its potential role in oral carcinogenesisA - a short report. ( 28653289 )
2017
32
Retrograde superselective intra-arterial chemotherapy and daily concurrent radiotherapy for T2-4N0 tongue cancer: control of occult neck metastasis. ( 28434836 )
2017
33
E3 ubiquitin ligase, RNF139, inhibits the progression of tongue cancer. ( 28662643 )
2017
34
Rising incidence of oral tongue cancer among white men and women in the United States, 1973-2012. ( 28351569 )
2017
35
Improving margin revision: Characterization of tumor bed margins in early oral tongue cancer. ( 29074194 )
2017
36
Swallowing Rehabilitation Affects Period of Hospitalization after Surgery for Tongue Cancer. ( 28381730 )
2017
37
Notch1 regulates tongue cancer cells proliferation, apoptosis and invasion. ( 29117785 )
2017
38
In vitro study on anti-cancer properties of genistein in tongue cancer. ( 29180873 )
2017
39
Decellularized tongue tissue as an in vitro model for studying tongue cancer and tongue regeneration. ( 28600128 )
2017
40
Bacteriome and mycobiome associations in oral tongue cancer. ( 29228609 )
2017
41
Targeted sequencing of tonsillar and base of tongue cancer and human papillomavirus positive unknown primary of the head and neck reveals prognostic effects of mutated FGFR3. ( 28525363 )
2017
42
Folatea89targeted polymeric micelles loaded with superparamagnetic iron oxide as a contrast agent for magnetic resonance imaging of a human tongue cancer cell line. ( 28944881 )
2017
43
Immunohistochemical analysis of EGFR and hyaluronan in tongue cancer and the development of regional recurrence in patients initially diagnosed N0. ( 28355940 )
2017
44
Comparative Analysis of MicroRNA Expression among Benign and Malignant Tongue Tissue and Plasma of Patients with Tongue Cancer. ( 28900608 )
2017
45
Contrast - enhanced ultrasound mapping of sentinel lymph nodes in oral tongue cancer - a pilot study. ( 28045344 )
2017
46
Isolated huge right ventricular tumor: cardiac metastasis of tongue cancer. ( 29036783 )
2017
47
Kikuchi-Fujimoto disease in the regional lymph nodes with node metastasis in a patient with tongue cancer: A case report and literature review. ( 28693162 )
2017
48
Prognostic significance of gene amplification of ACTN4 in stage I and II oral tongue cancer. ( 28385383 )
2017
49
Edema worsens target coverage in high-dose-rate interstitial brachytherapy of mobile tongue cancer: a report of two cases. ( 28344606 )
2017
50
Tenascin-C and fibronectin expression divide early stage tongue cancer into low- and high-risk groups. ( 28095396 )
2017

Variations for Tongue Cancer

Expression for Tongue Cancer

Search GEO for disease gene expression data for Tongue Cancer.

Pathways for Tongue Cancer

Pathways related to Tongue Cancer according to GeneCards Suite gene sharing:

(show all 34)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.84 CDKN1A PRLR TERT TP53 VEGFC
2
Show member pathways
12.71 CDH1 CDKN1A CDKN2A MMP9 TP53
3
Show member pathways
12.57 CDH1 CDKN1A CDKN2A TERT TP53
4
Show member pathways
12.51 CDH1 CDKN1A CDKN2A MMP2 MMP9 TP53
5
Show member pathways
12.41 CDH1 MMP2 MMP9 TP53
6 12.38 CDKN1A CDKN2A MMP9 TP53
7 12.28 CDKN1A CDKN2A TERT TP53
8 12.28 CDH1 CDKN1A CDKN2A MMP2 MMP9 TERT
9 12.2 CDH1 CDKN1A CDKN2A TP53
10 12.1 CDKN1A MMP2 MMP9 TP53
11 11.97 MMP2 MMP9 TP53
12 11.95 CDKN1A TERT TP53
13 11.94 CDKN1A MMP2 TP53
14 11.91 CDH1 MMP2 MMP9
15 11.87 CDKN1A CDKN2A TP53
16 11.87 CDH1 CDKN1A MMP2 MMP9 TP53
17 11.85 CDKN1A CDKN2A TP53
18 11.84 CDKN1A CDKN2A MMP2 TP53
19 11.82 CDKN1A CDKN2A TP53
20 11.79 CDKN1A MMP2 MMP9 TP53
21
Show member pathways
11.78 MMP2 MMP8 MMP9
22 11.72 MMP2 MMP9 VEGFC
23 11.67 MMP9 TERT TP53
24 11.6 CDKN1A CDKN2A TP53
25 11.52 CDH1 MMP2 MMP9 TERT
26 11.5 MMP2 MMP9 TERT
27 11.39 CDKN2A TP53 VEGFC
28 11.16 CDKN1A CDKN2A MMP2 TP53
29 11.02 MMP2 MMP9
30 11 CDKN2A TP53
31 10.96 CDH1 CDKN1A CDKN2A MMP2 MMP9 TP53
32
Show member pathways
10.92 CDKN1A CDKN2A TP53
33 10.68 CDKN1A TP53
34
Show member pathways
10.45 CDKN1A TP53

GO Terms for Tongue Cancer

Biological processes related to Tongue Cancer according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.85 CDKN1A MMP9 PRLR TERT TP53
2 cytokine-mediated signaling pathway GO:0019221 9.78 CDKN1A MMP2 MMP9 TP53
3 cell cycle arrest GO:0007050 9.71 CDKN1A CDKN2A TP53
4 negative regulation of cell growth GO:0030308 9.69 CDKN1A CDKN2A TP53
5 Ras protein signal transduction GO:0007265 9.61 CDKN1A CDKN2A TP53
6 collagen catabolic process GO:0030574 9.58 MMP2 MMP8 MMP9
7 response to X-ray GO:0010165 9.56 CDKN1A TP53
8 cellular senescence GO:0090398 9.55 CDKN1A CDKN2A
9 negative regulation of phosphorylation GO:0042326 9.52 CDKN1A CDKN2A
10 embryo implantation GO:0007566 9.5 MMP2 MMP9 PRLR
11 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.49 CDKN1A TP53
12 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.43 MMP2 MMP9 TERT
13 signal transduction by p53 class mediator GO:0072331 9.37 CDKN1A TP53
14 endodermal cell differentiation GO:0035987 9.33 MMP2 MMP8 MMP9
15 extracellular matrix disassembly GO:0022617 9.26 CDH1 MMP2 MMP8 MMP9
16 replicative senescence GO:0090399 8.92 CDKN1A CDKN2A TERT TP53

Molecular functions related to Tongue Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 metalloendopeptidase activity GO:0004222 9.13 MMP2 MMP8 MMP9
2 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 8.62 CDKN1A CDKN2A

Sources for Tongue Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....